NCT02928406已完成3 期
An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,004
- 试验地点
- 175
- 主要终点
- Percentage of Participants With Adverse Events (AEs)
研究概览
简要总结
This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with histologically documented locally advanced (tumor [T] 4b, any node [N]; or any T, N 2-3) or metastatic (M1, Stage IV) urothelial or non-urothelial carcinoma of the urinary tract
- •Participants with measurable and/or non-measurable disease according to RECIST v1.1
- •Participants must have progressed during or following treatment with at least one prior (and not more than 3) treatments for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
- •If available, a representative formalin-fixed paraffin-embedded (FFPE) tumor specimen block should be submitted
- •Eastern cooperative oncology group (ECOG) performance status 0, 1 or 2
排除标准
- •Treatment with more than three prior lines of systemic therapy for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
- •Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to study treatment initiation
- •Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were not on active drug in that prior trial are eligible
- •Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were in the follow-up phase of that prior trial and had stopped receiving active drug 4 or more weeks before study treatment initiation are eligible
- •Malignancies other than the one studied in this protocol within 5 years prior to Cycle 1, Day 1
- •Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol
- •Significant renal disorder indicating a need for renal transplant
研究组 & 干预措施
Atezolizumab
Experimental
Participants will receive atezolizumab every 3 weeks (Q3W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
干预措施: Atezolizumab (Drug)
结局指标
主要结局
Percentage of Participants With Adverse Events (AEs)
时间窗: Baseline up to end of study (up to approximately 6 years)
AEs were defined as any untoward medical occurrence in a subject administered a pharmaceutical product, regardless of causal attribution. An AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. New disease, exacerbation of existing disease, recurrence of an intermittent medical condition not present at baseline, any deterioration in a laboratory value or other clinical test associated with symptoms or leading to a change in study/concomitant treatment or discontinuation from study drug as well as events related to protocol-mandated interventions are considered AEs.
次要结局
- Percentage of Participants With Disease Control as Assessed by RECIST v1.1(Randomization up to disease progression or death from any cause, whichever occurred first (up to approximately 6 years))
- Percentage of Participants With Best Overall Response (BOR) as Assessed by RECIST v1.1(Randomization up to disease progression or death from any cause, whichever occurred first (up to approximately 6 years))
- Percentage of Participants With BOR as Assessed by Modified RECIST(Randomization up to disease progression or death from any cause, whichever occurred first (up to approximately 6 years))
- Overall Survival (OS)(Randomization until death from any cause (up to approximately 6 years))
- Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)(Randomization up to disease progression or death from any cause, whichever occurred first (up to approximately 6 years))
- PFS as Per Modified Response Evaluation Criteria in Solid Tumors (Modified RECIST)(Randomization up to disease progression or death from any cause, whichever occurred first (up to approximately 6 years))
- Percentage of Participants With Disease Control as Assessed by Modified RECIST(Randomization up to disease progression or death from any cause, whichever occurred first (up to approximately 6 years))
- Duration of Response (DOR) as Assessed by RECIST v1.1(Time from first occurrence of a documented response to disease progression or death from any cause, whichever occurred first (up to approximately 6 years))
- DOR as Assessed by Modified RECIST(Time from first occurrence of a documented response to disease progression or death from any cause, whichever occurred first (up to approximately 6 years))
- Change From Baseline in Health-Related Quality of Life (HRQoL), as Assessed Using European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score(Baseline, Day 1 of Cycles 1, 2, 3 and thereafter every 9 weeks for 54 weeks from study treatment start; and then every 12 weeks until progression/study discontinuation (up to approximately 6 years) (Cycle length = 21 days))
- Change From Baseline in European Quality of Life (EuroQoL) Group 5-Dimension 5-Level (EQ-5D-5L) Self Report Questionnaire Health Utility Score(Baseline, Day 1 of Cycles 1, 2, 3 and thereafter every 9 weeks for 54 weeks from study treatment start; and then every 12 weeks until progression/study discontinuation (up to approximately 6 years) (Cycle length = 21 days))
研究者
研究点 (175)
Loading locations...
相似试验
已完成
3 期
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]Squamous Non-Small Cell Lung CancerNCT02367794Hoffmann-La Roche1,021
已完成
2 期
A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"Non-Small Cell Lung CancerNCT01903993Hoffmann-La Roche287
已完成
2 期
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]Non-Small Cell Lung CancerNCT01846416Genentech, Inc.138
已完成
1 期
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid TumorsSolid CancersNCT02174172Hoffmann-La Roche158
终止
2 期
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung CancerNon-Small Cell Lung Cancer (NSCLC)NCT04832854Hoffmann-La Roche50